Walgreens Boots Alliance (WBA)
(Delayed Data from NSDQ)
$8.56 USD
-0.15 (-1.72%)
Updated Sep 23, 2024 03:57 PM ET
After-Market: $8.57 +0.01 (0.12%) 6:40 PM ET
4-Sell of 5 4
C Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.56 USD
-0.15 (-1.72%)
Updated Sep 23, 2024 03:57 PM ET
After-Market: $8.57 +0.01 (0.12%) 6:40 PM ET
4-Sell of 5 4
C Value D Growth C Momentum D VGM
Zacks News
Walgreens Boots Alliance (WBA) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
In the most recent trading session, Walgreens Boots Alliance (WBA) closed at $9.01, indicating a -0.55% shift from the previous trading day.
Walgreens Boots Alliance (WBA) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
The latest trading day saw Walgreens Boots Alliance (WBA) settling at $8.84, representing a +1.14% change from its previous close.
Why the Market Dipped But Walgreens Boots Alliance (WBA) Gained Today
by Zacks Equity Research
In the closing of the recent trading day, Walgreens Boots Alliance (WBA) stood at $8.77, denoting a +0.34% change from the preceding trading day.
Zacks Industry Outlook Highlights CVS Health, Walgreens Boots Alliance, Herbalife and Amazon
by Zacks Equity Research
CVS Health, Walgreens Boots Alliance, Herbalife and Amazon are part of the Zacks Industry Outlook article.
Walgreens Boots Alliance (WBA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Walgreens Boots Alliance (WBA) reachead $8.74 at the closing of the latest trading day, reflecting a +1.04% change compared to its last close.
3 Stocks to Avoid From The Volatile Retail Pharmacy Industry
by Urmimala Biswas
Zacks Retail-Pharmacies and Drug Stores industry players like CVS, WBA and HLF are likely to be affected by reimbursement challenges that are hurting the overall health of the industry.
CVS Stock Tanks 27.5% Year to Date: Time to Buy the Dip?
by Urmimala Biswas
While CVS Health has been grappling with pharmacy reimbursement pressure, a turnaround might be in the cards, given its several strategic initiatives.
Walgreens Boots Alliance (WBA) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
In the latest trading session, Walgreens Boots Alliance (WBA) closed at $10.38, marking a +0.78% move from the previous day.
Walgreens (WBA) Partners With BARDA to Boost Clinical Research
by Zacks Equity Research
Walgreens (WBA) and BARDA form a strategic partnership to bolster the decentralized clinical trial model.
Walgreens Boots Alliance (WBA) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
Walgreens Boots Alliance (WBA) closed at $10.92 in the latest trading session, marking a +0.92% move from the prior day.
Interactive Brokers and Walgreens Boots Alliance have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Interactive Brokers and Walgreens Boots Alliance are part of the Zacks Bull and Bear of the Day article.
Bear of the Day: Walgreens Boots Alliance (WBA)
by Derek Lewis
WBA has been a classic example of 'it can always go lower', with shares unable to find any traction over recent years.
The Zacks Analyst Blog CVS Health, Walgreens and Herbalife
by Zacks Equity Research
CVS Health, Walgreens and Herbalife are included in this Analyst Blog.
What is the Right Approach for CVS Health (CVS) Post Q2 Results?
by Urmimala Biswas
The near-term challenges for CVS Health (CVS) are no doubt worrisome. Yet, the company remains focused on its strategic moves, utilizing integrated healthcare models and technological advancements.
Company News for Aug 6, 2024
by Zacks Equity Research
Companies In The Article Are:CG, WBA, K and TSN
Walgreens Boots Alliance, Inc. (WBA) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Walgreens (WBA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
CVS Health (CVS) Stock Pre-Q2 Earnings: To Buy or Not to Buy?
by Urmimala Biswas
CVS Health (CVS) is grappling with a sudden increase in Medicare Advantage members' utilization trend. The Medicaid business, too, is expected to have experienced medical cost pressure in the second quarter.
CVS Health (CVS) Falls 24% in 3 Months: Should You Buy the Dip?
by Urmimala Biswas
While CVS Health (CVS) has been grappling with the pharmacy reimbursement pressure, a turnaround might be in the cards given its several strategic initiatives.
Super Micro Computer and Walgreens Boots Alliance have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Super Micro Computer and Walgreens Boots Alliance are part of the Zacks Bull and Bear of the Day article.
Bear of the Day: Walgreens Boots Alliance (WBA)
by Derek Lewis
Margin pressures and lowered guidance paint a challenging picture for the company's shares in the near term.
Walgreens Boots (WBA) Q3 Earnings Miss, Gross Margin Down
by Zacks Equity Research
An increasingly challenging pharmacy industry and consumer environment hurt Walgreens Boots' (WBA) bottom line in the third quarter of fiscal 2024.
Nike and Walgreens Boot Alliance are part of Zacks Earnings Preview
by Zacks Equity Research
Nike and Walgreens Boot Alliance are highlights of Zacks Earnings Preview article.
Q2 Earnings Growth Forecasted to Hit Two-Year High
by Sheraz Mian
Q2's expected quarterly earnings growth pace of +8.3% reflects the strongest growth since back in Q1 of 2022. Tech is expected to do some heavy lifting again, with earnings expected to be up +15.5% on +9.5% higher revenues.
Top and Flop ETFs of the First Half
by Sweta Killa
We have highlighted three ETFs each from the best and worst-performing zones in the first half of 2024.
Cencora (COR) Stock Nosedives: Here's What Caused the Decline
by Zacks Equity Research
Cencora (COR) shares declined on Jun 27, following an unfavorable ruling from the Supreme Court related to a previously settled litigation. Here we discuss the key factors that likely led to the decline.